Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin in GLUT1 Deficiency Syndrome
NCT02018315Phase 1Completed
- Start
- Jan 2012
- Primary completion
- Jan 2013
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of triheptanoin in Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS). Primary endpoint: Reduction in Spike-wave Fraction of the EEG Recording Time at 1 day. Started Jan 2012; status: completed.
02
Drugs
triheptanoin
03
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS)
Beyond the preview
Go deeper on NCT02018315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02018315.